Patents by Inventor Jane Schmidt
Jane Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10154995Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: August 23, 2017Date of Patent: December 18, 2018Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Publication number: 20180105503Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: August 29, 2017Publication date: April 19, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Publication number: 20170348310Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: August 23, 2017Publication date: December 7, 2017Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Patent number: 9771337Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: October 10, 2016Date of Patent: September 26, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Patent number: 9763942Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: June 29, 2016Date of Patent: September 19, 2017Assignees: Genentech, Inc., Array BioPharma Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Patent number: 9670208Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.Type: GrantFiled: June 29, 2016Date of Patent: June 6, 2017Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, John Gaudino, Indrani W. Gunawardana, Erik James Hicken, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Jacob Schwarz, Huifen Chen, Lewis Gazzard, Jane Schmidt, Steve Do
-
Publication number: 20170088526Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: October 10, 2016Publication date: March 30, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Patent number: 9499487Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: May 18, 2012Date of Patent: November 22, 2016Assignee: Theravance Biopharma R&D IP, LLCInventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Publication number: 20160303126Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: June 29, 2016Publication date: October 20, 2016Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
-
Publication number: 20160304519Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.Type: ApplicationFiled: June 29, 2016Publication date: October 20, 2016Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Adam Cook, John Gaudino, Indrani W. Gunawardana, Erik James Hicken, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Jacob Schwarz, Huifen Chen, Lewis Gazzard, Jane Schmidt, Steve Do
-
Patent number: 8853255Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: April 25, 2013Date of Patent: October 7, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Eric L. Stangeland, Jane Schmidt, Daisuke Roland Saito, Adam D. Hughes, Lori Jean Patterson
-
Publication number: 20140125479Abstract: Described is a caregiver alert that allows a caregiver to remotely monitor the condition and needs of a patient. The system includes a patient device that is adapted to receive a command from a patient and transmit an alert signal wirelessly. Additionally, the system includes a caregiver device adapted to receive the alert signal and generate an alert indicator to notify a caregiver that the patient is in need of assistance. Each of the patient device and caregiver device are formed as wristbands (or any other suitably convenient item) to be worn by a user.Type: ApplicationFiled: April 1, 2013Publication date: May 8, 2014Inventor: Shelley Jane Schmidt
-
Patent number: 8686184Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: May 18, 2012Date of Patent: April 1, 2014Assignee: Theravance, Inc.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Publication number: 20130237581Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: April 25, 2013Publication date: September 12, 2013Applicant: THERAVANCE, INC.Inventors: Eric L. Stangeland, Jane Schmidt, Daisuke Roland Saito, Adam D. Hughes, Lori Jean Patterson
-
Publication number: 20130178769Abstract: Described is a sexual stimulation device that allows a user to selectively change the exterior texture or pleasure pattern. The device includes a handle component with a first vibrating member extending from the handle component. The first vibrating member is operable for providing a vibration sensation. A first interchangeable sheath is provided with a first exterior texture. The first interchangeable sheath is adapted to detachably attach with the first vibrating member. Additionally, a second interchangeable sheath with a second exterior texture is provided. As was the case above, the second interchangeable sheath is adapted to detachably attach with the first vibrating member. Importantly, the second exterior texture is distinct from the first exterior texture.Type: ApplicationFiled: December 7, 2012Publication date: July 11, 2013Inventor: Shelley Jane Schmidt
-
Patent number: 8455665Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: August 17, 2012Date of Patent: June 4, 2013Assignee: Theravance, Inc.Inventors: Eric Stangeland, Jane Schmidt, Daisuke Roland Saito, Adam Hughes, Lori Jean Patterson
-
Publication number: 20120308588Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: December 6, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Publication number: 20120309985Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: August 17, 2012Publication date: December 6, 2012Applicant: THERAVANCE, INC.Inventors: Eric STANGELAND, Jane SCHMIDT, Daisuke Roland SAITO, Adam HUGHES, Lori Jean PATTERSON
-
Publication number: 20120309724Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: December 6, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Patent number: 8273786Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: July 14, 2010Date of Patent: September 25, 2012Assignee: Theravance, Inc.Inventors: Eric Stangeland, Jane Schmidt, Daisuke Roland Saito, Adam Hughes, Lori Jean Patterson